RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
ALISO VIEJO, Calif., March 27, 2024 (GLOBE NEWSWIRE) — (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing […]
PLBY Group Reports Fourth Quarter & Full Year 2023 Financial Results
Q4 Revenue of $39.4 Million, Net Loss of $3.8 Million & Adjusted EBITDA of $1.1 Million Amends Credit Facility to […]
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
MOUNTAIN VIEW, Calif., March 27, 2024 (GLOBE NEWSWIRE) — NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming […]
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on […]
Lesaka to Host Webcast and Conference Call to Review Third Quarter 2024 Results
JOHANNESBURG, South Africa, March 27, 2024 (GLOBE NEWSWIRE) — Lesaka Technologies, Inc. (“Lesaka” or the “Company”) (NasdaqGS:LSAK; JSE: LSK) today […]
Rumble Reports Fourth Quarter and Full Year 2023 Results
~ Full Year 2023 Revenue Increased 106% to $81.0 Million ~ ~ Fourth Quarter Average Monthly Active Users Sequentially Increased […]
Zoomcar Partners with ACKO Drive; Empowers Local Hosts to Increase Car Fleet on its Car-Sharing Marketplace Platform
BENGALURU, India, March 27, 2024 (GLOBE NEWSWIRE) — Zoomcar Holdings, Inc. (“Zoomcar” or the “Company”) (Nasdaq: ZCAR), the NASDAQ-listed leading […]
Gaia Reports Fourth Quarter and Full Year 2023 Results
BOULDER, Colo., March 27, 2024 (GLOBE NEWSWIRE) — Gaia, Inc. (NASDAQ: GAIA) (“Gaia” or the “Company”), a conscious media and […]
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the […]
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in […]
